We are developing inobrodib, a new drug to benefit people with cancer
investigated over time by the CellCentric team
Drug prioritised, advanced
Inobrodib in the clinic, to treat specific cancers
Inobrodib is a first-in-class oral anti-cancer drug that targets twin tumour drivers, p300/CBP. It is a small molecule, formulated as a capsule taken orally, in Phase I/II clinical trials.
p300/CBP are twin (paralogue) acetyl transferases and gene activating proteins that are known to play an important role in the progression of certain cancers.
Inobrodib is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer.
CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late-stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.
As we develop our new cancer drug, inobrodib, we listen to patients. Having an oral product that can be taken at home, reducing time spent at hospital, is a big differentiator.pic.twitter.com/DBQfrnrzW9